|
|
|
|
Publications 2002
|
- Aandahl EM, Moretto WJ, Haslett PA, Vang T, Bryn T, Tasken K, Nixon DF (2002) Inhibition of antigen-specific T cell proliferation and cytokine production by protein kinase A type I. J. Immunol. 169:802–808.
- Barbour JD, Wrin T, Grant RM, Martin JN, Segal MR, Petropoulos CJ, Deeks SG (2002) Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J. Virol. 76:11104–11112.
- Borra MT, O'Neill FJ, Jackson MD, Marshall B, Verdin E, Foltz KR, Denu JM (2002) Conserved enzymatic
production and biological effect of O-acetyl-ADP-ribose by silent information regulator 2-like NAD+-dependent deacetylases. J. Biol. Chem. 277:12632–12641.
- Bredt BM, Higuera-Alhino D, Shade SB, Hebert SJ, McCune JM, Abrams DI (2002) Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. J. Clin. Pharmacol. 42:82S–89S.
- Cavrois M, de Noronha C, Greene WC (2002) A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat. Biotechnol. 20:1151–1154.
- Chen L-f, Mu Y, Greene WC (2002) Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kB. EMBO J.21:6539–6548.
- Deeks SG, Barbour JD, Grant RM, Martin JN (2002) Duration
and predictors of CD4 T-cell gains in patients who continue combination
therapy despite detectable plasma viremia. AIDS 16:201–207.
- Deeks SG, Hoh R, Grant RM, Wrin T, Barbour JD, Narvaez A,
Cesar D, Abe K, Hanley MB, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein
MK (2002) CD4+ T cell kinetics and activation in human
immunodeficiency virus–infected patients who remain viremic despite long-term
treatment with protease inhibitor–based therapy. J. Infect. Dis. 185:315–323.
- Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A,
Clausse N, Blacher S, Verdin E, Foidart J-M, Nusgens BV, Castronovo V (2002) Histone deacetylase inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21:427–436.
- Dorr A, Kiermer V, Pedal A, Rackwitz H-R, Henklein P, Schubert U, Zhou M-M, Verdin E, Ott M (2002) Transcriptional synergy between Tat and PCAF is dependent on the binding of acetylated Tat to the PCAF bromodomain. EMBO J. 21:2715–2723.
- Empig CJ, Goldsmith MA (2002) Association of the caveola vesicular system with cellular entry by filoviruses. J. Virol. 76:5266–5270.
- Fischle W, Dequiedt F, Hendzel MJ, Guenther MG, Lazar MA, Voelter W, Verdin E (2002) Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell 9:45–57.
- Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, Kahn JO (2002) Time trends in primary HIV-1 drug resistance among recently infected persons. J. Am. Med. Assoc. 288:181–188.
- Greene WC, Peterlin BM (2002) Charting HIV’s remarkable voyage through the cell: Basic science as a passport to future therapy. Nat. Med. 8:673–680.
- Jekle A, Schramm B, Jayakumar P, Trautner V, Schols D, De Clercq E, Mills J, Crowe SM, Goldsmith MA (2002) Coreceptor phenotype of natural human immunodeficiency virus with Nef deleted evolves in vivo, leading to increased virulence. J. Virol. 76:6966–6973.
- Jennes W, Kestens L, Nixon DF, Shacklett BL (2002) Enhanced ELISPOT detection of antigen-specific T cell responses from cryopreserved specimens with addition of both IL-7 and IL-15 — the Amplispot assay. J. Immunol. Methods 270:99–108.
- Keir ME, Rosenberg MG, Sandberg JK, Jordan KA, Wiznia A, Nixon DF, Stoddart CA, McCune JM (2002) Generation of CD3+CD8low thymocytes in the HIV type 1-infected thymus. J. Immunol. 169:2788–2796.
- Keir ME, Stoddart CA, Linquist-Stepps V, Moreno ME, McCune JM (2002) IFN-a secretion by type 2 predendritic cells up-regulates MHC class I in the HIV-1-infected thymus. J. Immunol. 168:325–331.
- Keppler OT, Welte FJ, Ngo TA, Chin PS, Patton KS, Tsou C-L, Abbey NW, Sharkey ME, Grant RM, You Y, Scarborough JD, Ellmeier W, Littman DR, Stevenson M, Charo IF, Herndier BG, Speck RF, Goldsmith MA (2002) Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1. J. Exp. Med. 195:719–736.
- Klenerman P, Tolfvenstam T, Price DA, Nixon DF, Broliden K, Oxenius A (2002) T lymphocyte responses against human parvovirus B19: Small virus, big response. Pathol. Biol. 50:317–325.
- Larsson M, Wilkens DT, Fonteneau J-F, Beadle TJ, Merritt MJ, Kost RG, Haslett PAJ, Cu-Uvin S, Bhardwaj N, Nixon DF, Shacklett BL (2002) Amplification of low-frequency antiviral CD8 T cell responses using autologous dendritic cells. AIDS 16:171–180.
- Loré K, Sönnerborg A, Broström C, Goh L-e, Perrin L, McDade H, Stellbrink H-j, Gazzard B, Weber R, Napolitano LA, van Kooyk Y, Andersson J (2002) Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection. AIDS 16:683–692.
- Mujtaba S, He Y, Zeng L, Farooq A, Carlson JE, Ott M, Verdin E, Zhou M-M (2002) Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF bromodomain. Mol. Cell 9:575–586.
- Murphy JC, Fischle W, Verdin E, Sinclair JH (2002) Control of cytomegalovirus lytic gene expression by histone acetylation. EMBO J. 21:1112–1120.
- Napolitano LA, Lo JC, Gotway MB, Mulligan K, Barbour JD, Schmidt D, Grant RM, Halvorsen RA, Schambelan M, McCune JM (2002) Increased thymic mass in circulating naïve CD4 T cells in HIV-1-infected adults treated with growth hormone. AIDS 16:1103–1111.
- Neese RA, Misell LM, Turner S, Chu A, Kim J, Cesar D, Hoh R, Antelo F, Strawford A, McCune JM, Christiansen M, Hellerstein MK (2002) Measurement in vivo of proliferation rates of slow turnover cells by 2H2O labeling of the deoxyribose moiety of DNA. Proc. Natl. Acad. Sci. USA 99:15345–15350.
- Neuenburg JK, Brodt HR, Herndier BG, Bickel M, Bacchetti P, Price RW, Grant RM, Schlote W (2002) HIV-related neuropathology, 1985 to 1999: Rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 31:171–177.
- Ortiz GM, Hu J, Goldwitz JA, Chandwani R, Larsson M, Bhardwaj N, Bonhoeffer S, Ramratnam B, Zhang L, Markowitz MM, Nixon DF (2002) Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection. J. Virol. 76:411–415.
- Sandberg JK, Fast NM, Palacios EH, Fennelly G, Dobroszycki J, Palumbo P, Wiznia A, Grant RM, Bhardwaj N, Rosenberg MG, Nixon DF (2002) Selective loss of innate CD4+ Va24 natural killer T cells in human immunodeficiency virus infection. J.
Virol. 76:7528–7534.
- Schweighardt B, Ortiz GM, Grant RM, Wellons M, Miralles GD, Kostrikis LG, Bartlett JA, Nixon DF (2002) Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. AIDS 16:2342–2344.
- Schwer B, North BJ, Frye RA, Ott M, Verdin E (2002) The human silent information regulator (Sir)2 homolog hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide–dependent deacetylase. J. Cell Biol. 158:647–657.
- Shacklett BL (2002) Beyond 51Cr release: New methods for assessing HIV-1-specific CD8+ T cell responses in peripheral blood and mucosal tissues. Clin. Exp. Immunol. 130:172–182.
- Shacklett BL, Ling B, Veazey RS, Luckay A, Moretto WJ, Wilkens DT, Hu J, Israel ZR, Nixon DF, Marx PA (2002) Boosting of SIV-specific T-cell responses in rhesus macaques that resist repeated intravaginal challenge with SIV mac251. AIDS Res. Hum. Retroviruses 18:1081–1088.
- Shacklett BL, Means RE, Larsson M, Wilkens DT, Beadle TJ, Merritt MJ, Bhardwaj N, Palumbo PE, Skurnick JH, Louria DB, Nixon DF (2002) Dendritic cell amplification of HIV type 1-specific CD8+ T cell responses in exposed, seronegative heterosexual women. AIDS Res. Hum. Retroviruses 18:805–815.
-
Shacklett BL, Shaw KES, Adamson LA, Wilkens DT, Cox CA, Motefiori DC, Gardner MB, Sonigo P, Luciw PA (2002) Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251. J. Virol. 76:11365–11378.
- Sherman MP, de Noronha CMC, Williams SA, Greene WC (2002) Insights into the biology of HIV-1 viral protein R. DNA Cell Biol. 21:679–688.
- Sherman MP, Greene WC (2002) Slipping through the door: HIV entry into the nucleus. Microbes Infect. 4:67–73.
- Sherman MP, Schubert U, Williams SA, de Noronha CMC, Kreisberg JF, Henklein P, Greene WC (2002) HIV Vpr displays natural protein transducing properties: Implications for viral pathogenesis. Virology 302:95–105.
- Skurnick JH, Palumbo P, DeVico A, Shacklett BL, Valentine FT, Merges M, Kamin-Lewis R, Mestecky J, Denny T, Lewis GK, Lloyd J, Praschunus R, Baker A, Nixon DF, Stranford S, Gallo R, Vermund SH, Louria DB (2002) Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. J. Infect. Dis. 185:428–438.
- Snow JW, Abraham N, Ma MC, Abbey NW, Herndier B, Goldsmith MA (2002) STAT5 promotes multilineage hematolymphoid development in vivo through effects on early hematopoietic progenitor cells. Blood 99:95–101.
|
|
|
|
|
|
